BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 35969832)

  • 1. Vulvar Cancer Incidence in the United States and its Relationship to Human Papillomavirus Vaccinations, 2001-2018.
    Berenson AB; Chang M; Hawk ET; Ramondetta LM; Hoang T
    Cancer Prev Res (Phila); 2022 Nov; 15(11):777-784. PubMed ID: 35969832
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Update of HPV-associated female genital cancers in the United States, 1999-2004.
    Watson M; Saraiya M; Wu X
    J Womens Health (Larchmt); 2009 Nov; 18(11):1731-8. PubMed ID: 19951205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trends in Human Papillomavirus-Associated Cancers, Demographic Characteristics, and Vaccinations in the US, 2001-2017.
    Liao CI; Francoeur AA; Kapp DS; Caesar MAP; Huh WK; Chan JK
    JAMA Netw Open; 2022 Mar; 5(3):e222530. PubMed ID: 35294540
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Incidence of in situ and invasive vulvar cancer in the US, 1998-2003.
    Saraiya M; Watson M; Wu X; King JB; Chen VW; Smith JS; Giuliano AR
    Cancer; 2008 Nov; 113(10 Suppl):2865-72. PubMed ID: 18980209
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting human papillomavirus to reduce the burden of cervical, vulvar and vaginal cancer and pre-invasive neoplasia: establishing the baseline for surveillance.
    Nygård M; Hansen BT; Dillner J; Munk C; Oddsson K; Tryggvadottir L; Hortlund M; Liaw KL; Dasbach EJ; Kjær SK
    PLoS One; 2014; 9(2):e88323. PubMed ID: 24505474
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Annual Report to the Nation on the Status of Cancer, 1975-2009, featuring the burden and trends in human papillomavirus(HPV)-associated cancers and HPV vaccination coverage levels.
    Jemal A; Simard EP; Dorell C; Noone AM; Markowitz LE; Kohler B; Eheman C; Saraiya M; Bandi P; Saslow D; Cronin KA; Watson M; Schiffman M; Henley SJ; Schymura MJ; Anderson RN; Yankey D; Edwards BK
    J Natl Cancer Inst; 2013 Feb; 105(3):175-201. PubMed ID: 23297039
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trends in HPV- and non-HPV-associated vulvar cancer incidence, United States, 2001-2017.
    Mix JM; Gopalani SV; Simko S; Saraiya M
    Prev Med; 2022 Nov; 164():107302. PubMed ID: 36240909
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incidence of vulvar high-grade precancerous lesions and cancer in Denmark before and after introduction of HPV vaccination.
    Rasmussen CL; Thomsen LT; Aalborg GL; Kjaer SK
    Gynecol Oncol; 2020 Jun; 157(3):664-670. PubMed ID: 32276790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential role of human papillomavirus in the development of subsequent primary in situ and invasive cancers among cervical cancer survivors.
    Balamurugan A; Ahmed F; Saraiya M; Kosary C; Schwenn M; Cokkinides V; Flowers L; Pollack LA
    Cancer; 2008 Nov; 113(10 Suppl):2919-25. PubMed ID: 18980275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. US assessment of HPV types in cancers: implications for current and 9-valent HPV vaccines.
    Saraiya M; Unger ER; Thompson TD; Lynch CF; Hernandez BY; Lyu CW; Steinau M; Watson M; Wilkinson EJ; Hopenhayn C; Copeland G; Cozen W; Peters ES; Huang Y; Saber MS; Altekruse S; Goodman MT;
    J Natl Cancer Inst; 2015 Jun; 107(6):djv086. PubMed ID: 25925419
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk of human papillomavirus-associated cancers among persons with AIDS.
    Chaturvedi AK; Madeleine MM; Biggar RJ; Engels EA
    J Natl Cancer Inst; 2009 Aug; 101(16):1120-30. PubMed ID: 19648510
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women.
    Muñoz N; Kjaer SK; Sigurdsson K; Iversen OE; Hernandez-Avila M; Wheeler CM; Perez G; Brown DR; Koutsky LA; Tay EH; Garcia PJ; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Steben M; Bosch FX; Dillner J; Huh WK; Joura EA; Kurman RJ; Majewski S; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Lupinacci LC; Giacoletti KE; Sings HL; James MK; Hesley TM; Barr E; Haupt RM
    J Natl Cancer Inst; 2010 Mar; 102(5):325-39. PubMed ID: 20139221
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancers attributable to human papillomavirus infection.
    Grulich AE; Jin F; Conway EL; Stein AN; Hocking J
    Sex Health; 2010 Sep; 7(3):244-52. PubMed ID: 20719211
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disparities in human papillomavirus-related cancer incidence and survival among human immunodeficiency virus-infected Hispanics living in the United States.
    Ortiz AP; Engels EA; Nogueras-González GM; Colón-López V; Soto-Salgado M; Vargas A; Machin M; Shiels MS
    Cancer; 2018 Dec; 124(23):4520-4528. PubMed ID: 30345506
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial.
    ; Dillner J; Kjaer SK; Wheeler CM; Sigurdsson K; Iversen OE; Hernandez-Avila M; Perez G; Brown DR; Koutsky LA; Tay EH; García P; Ault KA; Garland SM; Leodolter S; Olsson SE; Tang GW; Ferris DG; Paavonen J; Lehtinen M; Steben M; Bosch FX; Joura EA; Majewski S; Muñoz N; Myers ER; Villa LL; Taddeo FJ; Roberts C; Tadesse A; Bryan JT; Maansson R; Lu S; Vuocolo S; Hesley TM; Barr E; Haupt R
    BMJ; 2010 Jul; 341():c3493. PubMed ID: 20647284
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaps and Opportunities to Improve Prevention of Human Papillomavirus-Related Cancers.
    Aninye IO; Berry-Lawhorn JM; Blumenthal P; Felder T; Jay N; Merrill J; Messman JB; Nielsen S; Perkins R; Rowen T; Saslow D; Trimble CL; Smith-McCune K
    J Womens Health (Larchmt); 2021 Dec; 30(12):1667-1672. PubMed ID: 34871035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Human papillomavirus genotype attribution for HPVs 6, 11, 16, 18, 31, 33, 45, 52 and 58 in female anogenital lesions.
    Serrano B; de Sanjosé S; Tous S; Quiros B; Muñoz N; Bosch X; Alemany L
    Eur J Cancer; 2015 Sep; 51(13):1732-41. PubMed ID: 26121913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Real-World Effectiveness of Human Papillomavirus Vaccination Against Vulvovaginal High-Grade Precancerous Lesions and Cancers.
    Dehlendorff C; Baandrup L; Kjaer SK
    J Natl Cancer Inst; 2021 Jul; 113(7):869-874. PubMed ID: 33377930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus type-distribution in vulvar and vaginal cancers and their associated precursors.
    Smith JS; Backes DM; Hoots BE; Kurman RJ; Pimenta JM
    Obstet Gynecol; 2009 Apr; 113(4):917-924. PubMed ID: 19305339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.
    Garland SM; Hernandez-Avila M; Wheeler CM; Perez G; Harper DM; Leodolter S; Tang GW; Ferris DG; Steben M; Bryan J; Taddeo FJ; Railkar R; Esser MT; Sings HL; Nelson M; Boslego J; Sattler C; Barr E; Koutsky LA;
    N Engl J Med; 2007 May; 356(19):1928-43. PubMed ID: 17494926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.